Table 2.
The relationship of AEG1 and other clinicopathological parameters in NSCLC
| NSCLC | Number | AEG1 negative (n, %) | AEG1 positive (n, %) | χ2 | P |
|---|---|---|---|---|---|
| Tissues | −2.875 | 0.004 | |||
| Normal tissues | 30 | 23 (76.7) | 7 (23.3) | ||
| NSCLC | 339 | 167 (49.3) | 172 (50.7) | ||
| Gender | −0.969 | 0.332 | |||
| Male | 254 | 129 (50.8) | 125 (49.2) | ||
| Female | 85 | 38 (44.7) | 47 (55.3) | ||
| Age (years) | −0.616 | 0.538 | |||
| <60 | 181 | 92 (50.8) | 89 (49.2) | ||
| ≥60 | 158 | 75 (47.5) | 83 (52.5) | ||
| Tumor size | −4.414 | <0.001 | |||
| >7 | 44 | 8 (18.2) | 36 (81.8) | ||
| ≤7 | 295 | 159 (53.4) | 136 (46.1) | ||
| TNM | −3.019 | 0.003 | |||
| I–II | 286 | 151 (52.8) | 135 (47.2) | ||
| III–IV | 53 | 16 (30.2) | 37 (69.8) | ||
| LNM | −4.274 | <0.001 | |||
| Yes | 115 | 38 (33.0) | 77 (67) | ||
| No | 224 | 129 (57.6) | 95 (42.4) | ||
| Distal metastasis | −1.474 | 0.140 | |||
| Absent | 323 | 162 (50.2) | 161 (49.8) | ||
| Present | 16 | 5 (31.3) | 11 (68.7) | ||
| Pathological grading | 0.648a | 0.723 | |||
| I | 39 | 20 (51.3) | 19 (48.7) | ||
| II | 92 | 51 (55.4) | 41 (44.6) | ||
| III | 130 | 65 (50) | 65 (50) | ||
| Histology | 3.090 | 0.543 | |||
| 127 | 59 (46.5) | 68 (53.5) | |||
| 175 | 92 (52.6) | 83 (47.4) | |||
| 28 | 12 (42.9) | 16 (57.1) | |||
| 8 | 3 (37.5) | 5 (62.5) | |||
| 1 | 1 (100) | 0 (0.00) | |||
| Adenocarcinoma classification | 9.054 | 0.029 | |||
| Acinar adenocarcinoma | 83 | 42 (50.6) | 41 (49.4) | −2.464 | 0.014 |
| Broncholoalveolar | 18 | 5 (27.8) | 13 (72.2) | −3.291 | 0.001 |
| Papillary adenocarcinoma | 19 | 6 (31.6) | 13 (68.4) | −3.097 | 0.002 |
| Mucinous carcinoma | 7 | 6 (85.7) | 1 (14.3) | −0.516 | 0.719 |
Pathological grading I vs. II: Z = −0.435, P = 0.664; I vs. III: Z = −0.142, P = 0.889; II vs. III: Z = −0.797, P = 0.426.
NSCLC non-small-cell lung cancer, AEG-1 astrocyte elevated gene-1, TNM tumor node metastasis, LNM lymph node metastasis.
aKruskal–Wallis H test was performed.